CD274 and melanoma: In melanoma, more responses were observed in PD-L1–negative archival tumors (15 of 39 [38%]) as compared with PD-L1–positive archival tumors(4 of 27 [15%]). PD-L1 negative patients will benefit more with the combination treatment and can be considered as a potential biomarker. NCT02743819.